Literature DB >> 11440787

Clinical impact of histidine-ketoglutarate-tryptophan (HTK) cardioplegic solution on the perioperative period in open heart surgery patients.

G Careaga1, D Salazar, S Téllez, O Sánchez, G Borrayo, R Argüero.   

Abstract

BACKGROUND: Ischemia-reperfusion injury during open heart surgery related to unsuccessful myocardial protection may increase morbidity or mortality. We analyze the clinical outcome after cardiac surgery with a cardioplegic solution based on intracellular components added with histidine-ketoglutarate-tryptophan.
METHODS: Thirty patients programmed for elective open heart surgery were randomized into two groups. In group I (n = 15), myocardial protection was carried out with Bretschenider solution (HTK), and in group II (n = 15) with conventional crystalloid cardioplegia. The incidence of arrhythmias, inotropic support requirement, and length-of-stay in the intensive care unit were evaluated.
RESULTS: During reperfusion, there was no difference in incidence of arrhythmias; however, in the postoperative period group I had a lower incidence of arrhythmias (p = 0.001). Inotropic support (p = 0.003) and length-of-stay in the intensive care unit (p = 0.037) were lower in group I. There were no deaths in either group.
CONCLUSIONS: It was concluded that myocardial protection with Bretschneider solution effectively decreases incidence of arrhythmias, inotropic support, and length-of-stay in the intensive care unit.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11440787     DOI: 10.1016/s0188-4409(01)00296-x

Source DB:  PubMed          Journal:  Arch Med Res        ISSN: 0188-4409            Impact factor:   2.235


  13 in total

Review 1.  Is there a rationale for short cardioplegia re-dosing intervals?

Authors:  Yves D Durandy
Journal:  World J Cardiol       Date:  2015-10-26

Review 2.  Custodiol for myocardial protection and preservation: a systematic review.

Authors:  J James B Edelman; Michael Seco; Ben Dunne; Shannon J Matzelle; Michelle Murphy; Pragnesh Joshi; Tristan D Yan; Michael K Wilson; Paul G Bannon; Michael P Vallely; Jurgen Passage
Journal:  Ann Cardiothorac Surg       Date:  2013-11

3.  Clinical comparative analysis of histidine-tryptophan-ketoglutarate solution and St. Thomas crystalloid cardioplegia: A 12-year study from a single institution.

Authors:  Ying-Zhong Lin; Jing-Bin Huang; Xiang-Wei Li; Xian-Ming Tang; Wei-Jun Lu; Zhao-Ke Wen; Jian Liang; Dian-Yuan Li; Hao Wang
Journal:  Exp Ther Med       Date:  2017-07-19       Impact factor: 2.447

4.  Transport viable heart tissue at physiological temperature yielded higher human cardiomyocytes compared to the conventional temperature.

Authors:  Muhammad Arza Putra; Normalina Sandora; Retno Wahyu Nurhayati; Raisa Nauli; Tyas Rahmah Kusuma; Nur Amalina Fitria; Chaidar Muttaqin; William Makdinata; Idrus Alwi
Journal:  Cell Tissue Bank       Date:  2022-01-07       Impact factor: 1.522

5.  Custodiol-N, the novel cardioplegic solution reduces ischemia/reperfusion injury after cardiopulmonary bypass.

Authors:  Gábor Veres; Tamás Radovits; Béla Merkely; Matthias Karck; Gábor Szabó
Journal:  J Cardiothorac Surg       Date:  2015-02-28       Impact factor: 1.637

6.  Histidine and other amino acids in blood and urine after administration of Bretschneider solution (HTK) for cardioplegic arrest in patients: effects on N-metabolism.

Authors:  Johanna K Teloh; Daniel-Sebastian Dohle; Miriam Petersen; Rabea Verhaegh; Indra N Waack; Friederike Roehrborn; Heinz Jakob; Herbert de Groot
Journal:  Amino Acids       Date:  2016-02-27       Impact factor: 3.520

7.  Bretschneider solution-induced alterations in the urine metabolome in cardiac surgery patients.

Authors:  Cheng-Chia Lee; Ya-Ju Hsieh; Shao-Wei Chen; Shu-Hsuan Fu; Chia-Wei Hsu; Chih-Ching Wu; Wei Han; Yunong Li; Tao Huan; Yu-Sun Chang; Jau-Song Yu; Liang Li; Chih-Hsiang Chang; Yi-Ting Chen
Journal:  Sci Rep       Date:  2018-12-11       Impact factor: 4.379

8.  Lung Protection Strategies during Cardiopulmonary Bypass Affect the Composition of Blood Electrolytes and Metabolites-A Randomized Controlled Trial.

Authors:  Katrine B Buggeskov; Raluca G Maltesen; Bodil S Rasmussen; Munsoor A Hanifa; Morten A V Lund; Reinhard Wimmer; Hanne B Ravn
Journal:  J Clin Med       Date:  2018-11-21       Impact factor: 4.241

9.  Comparative Analysis of Myocardial Protection with HTK Solution and Hypothermic Hyperkalemic Blood Solution in the Correction of Acyanogenic Congenital Cardiopathies - A Randomized Study.

Authors:  Acrisio Sales Valente; Gustavo Porto Lustosa; Lia Alves Martins Mota; Adriano Lima; Fernando Antônio de Mesquita; Aloísio Gondim; Fábio Alércio Rodrigues; Ronald Guedes Pompeu; Klébia Castelo Branco
Journal:  Braz J Cardiovasc Surg       Date:  2019-06-01

10.  Histidine-tryptophan-ketoglutarate solution decreases mortality and morbidity in high-risk patients with severe pulmonary arterial hypertension associated with complex congenital heart disease: an 11-year experience from a single institution.

Authors:  X W Li; Y Z Lin; H Lin; J B Huang; X M Tang; X M Long; W J Lu; Z K Wen; J Liang; D Y Li; X F Zhao
Journal:  Braz J Med Biol Res       Date:  2016-05-13       Impact factor: 2.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.